Information  X 
Enter a valid email address

Amryt Pharma PLC Ord 6P Ord Ne (AMYT)

Related News

11-May-2020 08:10 AM

Amryt reports wider losses, but says performance exceeding expectations as revenue jumps 30%

Biopharmaceutical company Amryt said its performance was exceeding its expectations so far this year despite reporting higher losses on increased costs in the first quarter even as revenue and earnings grew strongly. In the first quarter, the company re
17-Apr-2019 02:08 PM

Amryt Pharma books annual loss as R&D, marketing costs weigh

Amryt Pharma booked a full-year loss after rising revenue was more than offset by R&D, marketing and administrative costs. Pre-tax losses for the year through December amounted to €25.7m, compared to losses of €26.1m on-year. Revenue rose 13%
26-Sep-2018 02:41 PM

Amryt Pharma posts loss as spending offsets revenue growth

Orphan drug company Amryt Pharma posted a first-half loss after rising revenue was offset by administrative and R&D spending. Pre-tax losses for the six months through June amounted to €11.4m, narrowing from losses of €13.8m on-year. Revenue r
10-Jan-2018 09:31 AM

Amryt inks distribution deal with GryNumber

Amryt Pharma has signed an exclusive distribution agreement covering central and eastern Europe with GryNumber Health which further expands the route to market for Lojuxta (lomitapide). Amryt said the agreement covers the distribution of Lojuxta across A
13-Nov-2017 09:45 AM

Amryt inks Saudi Arabia distribution agreement

Amryt Pharma has signed a distributorship agreement with Faisal Musaed El Seif Saudi Pharmaceutical Co, for Amryt's products in Saudi Arabia. Amryt said this exclusive agreement covered Lojuxta (lomitapide) and AP101, the company's clinical st
09-Oct-2017 01:02 PM

Amryt Pharma shareholders pass all resolutions at today's GM

Amryt Pharma has confirmed that all resolutions were passed by shareholders at today's General Meeting. As a result, shareholders have granted the Company's directors the authority to allot and issue, and the Company's directors have resol
04-Sep-2017 09:40 AM

Broker Forecast - Beaufort Securities issues a broker note on Amryt Pharma

Beaufort Securities today reaffirms its speculative buy investment rating on Amryt Pharma (LON:AMYT) and raised its price target to 65p (from 62p). Story provided by StockMarketWire.com...
04-Sep-2017 07:31 AM

Amryt Pharma losses widen

Amryt Pharma's losses on ordinary activities before tax rose to €13.8m in the six months to the end of June- up from $4.1m last time. It said this year's figure included a non-cash charge of €7.7m, relating to contingent consideration
23-Aug-2017 09:12 AM

Amryt Pharma schedules interims

Amryt Pharma will announce its results for the six months ended 30 June on 4 September. At 9:12am: (LON:AMYT) Amryt Pharma share price was -0.25p at 20.75p Story provided by StockMarketWire.com...
25-Jul-2017 09:48 AM

Study shows positive results for Amryt 'bad cholesterol' drug

Amryt Pharma aid a newly published long-term study showed highly positive results for Lojuxta, the company's in-licensed drug used in the treatment of homozygous familial hypercholesterolaemia, a rare, genetic, life-threatening disease, which impairs
25-May-2017 02:14 PM

Amryt resolutions passed at today's AGM

Amryt Pharma has confirmed that all resolutions were passed at today's Annual General Meeting. At 2:14pm: (LON:AMYT) Amryt Pharma share price was +1.63p at 27.5p Story provided by StockMarketWire.com...
23-May-2017 10:30 AM

Broker Forecast - Beaufort Securities issues a broker note on Amryt Pharma

Beaufort Securities today reaffirms its speculative buy investment rating on Amryt Pharma (LON:AMYT) and set its price target at 62p. Story provided by StockMarketWire.com...
27-Apr-2017 09:52 AM

Study confirms efficacy of Lojuxta, says Amryt

Amryt Pharma has announced the publication of study results which evaluated the benefits of Lojuxta (lomitapide) in the treatment of Homozygous Familial Hypercholesterolaemia, a rare, life-threatening disease, which impairs the body's ability to rem
30-Mar-2017 09:15 AM

Amryt pre-tax losses rise

Amryt Pharma's pre-tax losses rose to €7.8m in the year to the end of December compared with €1.2m last time. Revenues for the year totalled €1,351,000 and comprised approximately one month's contribution from Lojuxta as well as
28-Mar-2017 09:21 AM

Amryt starts phase 3 clinical trial

Amryt Pharma has started EASE, its phase 3 clinical trial of AP101, the group's lead drug candidate, which offered a potential treatment for Epidermolysis Bullosa. EB is a rare, genetic skin disorder, which causes exceptionally fragile skin. The co
08-Mar-2017 09:54 AM

Amryt Pharma schedules FY results

Amryt Pharma expects to announce its results for the year ended 31 December on 30 March. At 9:54am: (LON:AMYT) Amryt Pharma share price was 0p at 19p Story provided by StockMarketWire.com...
06-Mar-2017 09:44 AM

Amryt to start clinical trial of EB treatment

Amryt Pharma is set to start a phase 3 clinical trial for AP101 as a potential treatment for Epidermolysis Bullosa have completed pre-trial discussions with the Food and Drug Administration and European Medicines Agency. EB is a rare genetic skin disorde
07-Feb-2017 09:32 AM

Amryt Pharma granted Japan patent

Amryt Pharma, the pharmaceutical company focused on best-in-class treatments for rare and orphan diseases, has been granted a patent in Japan for its lead drug candidate, AP101 (Episalvan), for the treatment of Epidermolysis Bullosa (EB), a rare genetic s
06-Feb-2017 07:34 AM

Amryt reports positive pre-clinical study results

Amryt Pharma reports positive results of a newly completed pre-clinical study that compared its drug compound AP102 - a somatostatin analogue therapy with the potential to treat acromegaly - with pasireotide, an approved product for treating patients wit
02-Dec-2016 07:54 AM

Amryt €20m facility with EIB

Amryt Pharma says it has entered into a €20m facility agreement with the European Investment Bank on highly attractive terms for the company. Amryt says the facility is significant because it provides non-dilutive funding that secures the company&a
07-Nov-2016 08:16 AM

Amryt granted orphan drug designation by FDA

Amryt Pharma's drug compound AP102, which has the potential to treat patients with acromegaly, has been granted orphan drug designation by the US Food and Drug Administration. Acromegaly is a rare endocrine disorder in which the body produces exces
13-Sep-2016 09:40 AM

Amryt granted US patent

Amryt Pharma has been granted a US patent for its lead drug, Episalvan, in the treatment of Epidermolysis Bullosa. EB is a rare and distressing hereditary skin disorder, which leads to mechanical fragility of skin. All forms are considered serious
09-Jun-2016 09:07 AM

Amryt Pharma posts loss

Amryt Pharma posts a net loss of €2.5m for the nine months to the end of December against a loss of €36.0m for the year to the end of March 2015). The loss comprises general and administrative costs of €1.3m and discontinued oil and gas
03-Jun-2016 08:51 AM

Amryt Pharma schedules 9M results

Amryt Pharma will announce its results for the nine months ended 31 December on 9 June. At 8:51am: (LON:AMYT) Amryt Pharma share price was 0p at 19p Story provided by StockMarketWire.com...
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t